Amgen

Leukaemia
#Amgen #Haematology #Mergers and acquisitions #Oncology

Amgen acquires Dark Blue Therapeutics for $840 million

Oncology biotech Dark Blue Therapeutics has been acquired by Amgen for up to $840 million, including upfront and future milestones.  Dark Blue’s lead candidate DBT 3757, currently in IND-enabling studies, represents a first-in-class therapeutic strategy for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), with the… Read More

#Business & Investment #News

Woman with a nose bleed
#Amgen #AstraZeneca #European Union

Tezspire approved in EU for ‘challenging’ rhinosinusitis  

AstraZeneca and Amgen’s Tezspire (tezepelumab) has been approved in the European Union for chronic rhinosinusitis with nasal polyps.  Tezspire has been approved as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately… Read More

#News #Regulatory

Amgen HQ
#Amgen #Autoimmune disease #Immune system #Phase III trial

Amgen reports positive results for treatment of IgG4-RD

Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD). The company’s MITIGATE study was designed to evaluate the safety and efficacy of UPLINZA compared to placebo… Read More

#News